CABA Stock Chart & Stats
$50.00
$0.00(0.00%)
At close: 4:00 PM EDT
$50.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$35.00 - $67.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$7.60B
Enterprise Value$270.72
Total Cash (Recent Filing)$225.10M
Total Debt (Recent Filing)$25.71M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Nov 05, 2026EPS Estimate
-5.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding169,545,440
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$253.23Price Target Upside406.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-23.17
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Improved EquityRelatively modest debt compared with equity gives Cabaletta Bio greater solvency and financial flexibility during clinical development. The rebound in equity also strengthens its capacity to support research programs and absorb operating volatility while it remains pre-commercial.
Material Liquidity InfusionThe substantial warrant proceeds provide an important funding buffer for ongoing development programs and operating needs. Greater liquidity can extend execution capacity and reduce immediate financing pressure, which is particularly valuable for a clinical-stage company with no product revenue.
Focused Autoimmune Cell-therapy PipelineA focused pipeline targeting B cell-mediated autoimmune diseases gives the company a coherent development strategy rather than a broad, diffuse portfolio. Addressing several serious conditions with related biology may support platform leverage and strengthen the long-term opportunity if clinical results validate the approach.
Bears Say
No Commercial RevenueWith no approved products or recurring sales, Cabaletta Bio lacks commercial revenue to fund operations and validate market adoption. Progress therefore remains dependent on clinical development and future financing or collaboration proceeds, leaving the business model materially exposed until a program reaches commercialization.
Widening Operating LossesThe multi-year expansion in net losses indicates that development spending is rising faster than any offsetting revenue, because revenue remains absent. Persistently negative profitability reduces internal funding capacity and increases the capital required to advance multiple clinical programs over the next several quarters.
Heavy And Worsening Cash BurnCash generation is a durable pressure point because operating and free cash flow have deteriorated substantially over time and closely track net losses. This level of burn implies continued financing needs, potentially creating dilution or restricting the pace and breadth of future clinical investment.
Cabaletta Bio News
CABA FAQ
What was Cabaletta Bio’s price range in the past 12 months?
Cabaletta Bio lowest stock price was $35.00 and its highest was $67.00 in the past 12 months.
What is Cabaletta Bio’s market cap?
Cabaletta Bio’s market cap is $7.60B.
When is Cabaletta Bio’s upcoming earnings report date?
Cabaletta Bio’s upcoming earnings report date is Nov 05, 2026 which is in 49 days.
How were Cabaletta Bio’s earnings last quarter?
Cabaletta Bio released its earnings results on Aug 13, 2026. The company reported -$5.792 earnings per share for the quarter, beating the consensus estimate of -$6.354 by $0.562.
Is Cabaletta Bio overvalued?
According to Wall Street analysts Cabaletta Bio’s price is currently Undervalued.
Does Cabaletta Bio pay dividends?
Cabaletta Bio does not currently pay dividends.
What is Cabaletta Bio’s EPS estimate?
Cabaletta Bio’s EPS estimate is -5.4.
How many shares outstanding does Cabaletta Bio have?
Cabaletta Bio has 169,545,440 shares outstanding.
What happened to Cabaletta Bio’s price movement after its last earnings report?
Cabaletta Bio reported an EPS of -$5.792 in its last earnings report, beating expectations of -$6.354. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cabaletta Bio?
Currently, no hedge funds are holding shares in MX:CABA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cabaletta Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$253.23 (406.45% Upside)
$253.23 (406.45% Upside)
Blogger Sentiment
Bullish
MX:CABA Sentiment 100%
Sector Average 62%
Sector Average 62%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.36%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cabaletta Bio
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
CABA Stock 12 Month Forecast
Average Price Target
$253.23
▲(406.45% Upside)